Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice
Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…Striatal Blood brain barrier opening in Parkinson´s disease
Objective: To test safety and feasibility of repeated low-intensity focused ultrasound (FUS) blood brain barrier opening (BBB) in the striatum of Parkinson’s disease (PD) patients.…Use of alternative healing for Parkinson’s disease in Kenya
Objective: To explore the experience of alternative healing practices by people with Parkinson’s disease in Kenya. Background: As a neurodegenerative condition, Parkinson’s disease (PD) requires…Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Objective: To evaluate the pharmacodynamic (PD) and safety profiles of subcutaneous (SC) administration of multiple ascending doses of CTI-1601 in patients age ≥18 years with…Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Exosomes from human dental pulp stem cells as a cell-free drug delivery vehicle in vitro and in vivo chronic PD rat model through the intranasal route targeting efficacy & bio-distribution.
Objective: To evaluate the drug encasement in human dental pulp stem cell derived exosomes and its delivery in vitro in single cell level using fluorescence…IS THE HYPOXIA EXPOSURE BENEFICIAL FOR PEOPLE WITH PARKINSON’S DISEASE? A SCOPE REVIEW
Objective: To explore the current evidence and identify knowledge gaps, we conducted a scoping review about the hypoxia exposure effects on people with Parkinson’s disease…Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome
Objective: To evaluate the long-term safety and activity of ecopipam (ECO) in the treatment of children and adolescents with Tourette syndrome (TS). Background: D2 antagonists…Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8
Objective: To determine the effects of the nanocatalytic drug, CNM-Au8, on brain energy metabolites in Parkinson’s Disease. Background: Converging lines of evidence are identifying brain…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »